Browse CTH

Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF01053 Cys/Met metabolism PLP-dependent enzyme
Function

Catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine. Has broad substrate specificity. Converts cystathionine to cysteine, ammonia and 2-oxobutanoate. Converts two cysteine molecules to lanthionine and hydrogen sulfide. Can also accept homocysteine as substrate. Specificity depends on the levels of the endogenous substrates. Generates the endogenous signaling molecule hydrogen sulfide (H2S), and so contributes to the regulation of blood pressure. Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function.

> Gene Ontology
 
Biological Process GO:0000096 sulfur amino acid metabolic process
GO:0000098 sulfur amino acid catabolic process
GO:0006520 cellular amino acid metabolic process
GO:0006534 cysteine metabolic process
GO:0006555 methionine metabolic process
GO:0006790 sulfur compound metabolic process
GO:0006986 response to unfolded protein
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0008652 cellular amino acid biosynthetic process
GO:0009066 aspartate family amino acid metabolic process
GO:0009067 aspartate family amino acid biosynthetic process
GO:0009069 serine family amino acid metabolic process
GO:0009070 serine family amino acid biosynthetic process
GO:0009086 methionine biosynthetic process
GO:0009092 homoserine metabolic process
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0018065 protein-cofactor linkage
GO:0018205 peptidyl-lysine modification
GO:0018272 protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysine
GO:0018352 protein-pyridoxal-5-phosphate linkage
GO:0019343 cysteine biosynthetic process via cystathionine
GO:0019344 cysteine biosynthetic process
GO:0019346 transsulfuration
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035886 vascular smooth muscle cell differentiation
GO:0035887 aortic smooth muscle cell differentiation
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0042692 muscle cell differentiation
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0044524 protein sulfhydration
GO:0046394 carboxylic acid biosynthetic process
GO:0050667 homocysteine metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051145 smooth muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051150 regulation of smooth muscle cell differentiation
GO:0051152 positive regulation of smooth muscle cell differentiation
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0070813 hydrogen sulfide metabolic process
GO:0070814 hydrogen sulfide biosynthetic process
GO:0071265 L-methionine biosynthetic process
GO:0071266 'de novo' L-methionine biosynthetic process
GO:1901342 regulation of vasculature development
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901607 alpha-amino acid biosynthetic process
GO:1904018 positive regulation of vasculature development
GO:1904829 regulation of aortic smooth muscle cell differentiation
GO:1904831 positive regulation of aortic smooth muscle cell differentiation
GO:1905063 regulation of vascular smooth muscle cell differentiation
GO:1905065 positive regulation of vascular smooth muscle cell differentiation
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
Molecular Function GO:0003962 cystathionine gamma-synthase activity
GO:0004123 cystathionine gamma-lyase activity
GO:0005516 calmodulin binding
GO:0016765 transferase activity, transferring alkyl or aryl (other than methyl) groups
GO:0016829 lyase activity
GO:0016846 carbon-sulfur lyase activity
GO:0030170 pyridoxal phosphate binding
GO:0043168 anion binding
GO:0044540 L-cystine L-cysteine-lyase (deaminating)
GO:0047982 homocysteine desulfhydrase activity
GO:0048037 cofactor binding
GO:0080146 L-cysteine desulfhydrase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00260 Glycine, serine and threonine metabolism
hsa00270 Cysteine and methionine metabolism
hsa00450 Selenocompound metabolism
hsa01100 Metabolic pathways
hsa01230 Biosynthesis of amino acids
Reactome R-HSA-1614603: Cysteine formation from homocysteine
R-HSA-1614558: Degradation of cysteine and homocysteine
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-2408508: Metabolism of ingested SeMet, Sec, MeSec into H2Se
R-HSA-2408522: Selenoamino acid metabolism
R-HSA-1614635: Sulfur amino acid metabolism
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CTH and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CTH in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CTH in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4550.181
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4630.696
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4550.573
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.640.141
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0240.363
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1590.902
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0630.866
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0190.984
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0490.965
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2470.716
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4450.644
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2660.0939
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CTH in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTH. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTH. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTH.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTH. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CTH expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CTH and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCTH
Namecystathionine gamma-lyase
Aliases cystathionase (cystathionine gamma-lyase); cysteine desulfhydrase; cysteine-protein sulfhydrase; gamma-cysta ......
Chromosomal Location1p31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CTH collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CTH.
ID Name Drug Type Targets #Targets
DB00114Pyridoxal PhosphateSmall MoleculeAADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......54
DB00151L-CysteineSmall MoleculeCARS, CARS2, CBS, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NF ......13
DB023282-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic AcidSmall MoleculeCTH1
DB03928Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-OxadiazolSmall MoleculeCTH1
DB04217L-2-amino-3-butynoic acidSmall MoleculeCTH1